S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
Is This The End of Capitalism? (Ad)
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
Is This The End of Capitalism? (Ad)
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
The Next Big Crisis Is Here (Ad)
Mergers and Acquisitions in 2023 Off To A Strong Start
Chevron Delights Shareholders with $75 Billion in Share Buybacks
S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
Is This The End of Capitalism? (Ad)
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
Is This The End of Capitalism? (Ad)
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
The Next Big Crisis Is Here (Ad)
Mergers and Acquisitions in 2023 Off To A Strong Start
Chevron Delights Shareholders with $75 Billion in Share Buybacks
S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
Is This The End of Capitalism? (Ad)
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
Is This The End of Capitalism? (Ad)
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
The Next Big Crisis Is Here (Ad)
Mergers and Acquisitions in 2023 Off To A Strong Start
Chevron Delights Shareholders with $75 Billion in Share Buybacks
S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
Is This The End of Capitalism? (Ad)
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
Is This The End of Capitalism? (Ad)
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
The Next Big Crisis Is Here (Ad)
Mergers and Acquisitions in 2023 Off To A Strong Start
Chevron Delights Shareholders with $75 Billion in Share Buybacks
NASDAQ:SAGE

Sage Therapeutics - SAGE Stock Forecast, Price & News

$44.97
+0.46 (+1.03%)
(As of 01/26/2023 12:00 AM ET)
Add
Compare
Today's Range
$43.40
$45.16
50-Day Range
$35.05
$45.58
52-Week Range
$27.36
$49.56
Volume
384,752 shs
Average Volume
445,285 shs
Market Capitalization
$2.68 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$48.29

Sage Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
7.4% Upside
$48.29 Price Target
Short Interest
Healthy
7.52% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.37
Upright™ Environmental Score
News Sentiment
0.21mentions of Sage Therapeutics in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($8.90) to ($8.71) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.92 out of 5 stars

Medical Sector

862nd out of 1,048 stocks

Pharmaceutical Preparations Industry

428th out of 513 stocks


SAGE stock logo

About Sage Therapeutics (NASDAQ:SAGE) Stock

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel medicines. It targets diseases and disorders of the brain with three key focus areas: depression, neurology, and neuropsychiatry. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010, and is headquartered in Cambridge, MA.

Receive SAGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sage Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SAGE Stock News Headlines

The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Sage Therapeutics
Sage Therapeutics Could Be In For A Depressing FDA Review
Sage Therapeutics: Zuranolone NDA Near-Term Tailwind
Mizuho Securities Keeps Their Hold Rating on SAGE Therapeutics (SAGE)
Sage Therapeutics Recent Insider Activity
What to know about Biogen's new CEO
Here are three things to know about Biogen's new CEO
See More Headlines
Receive SAGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sage Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SAGE Company Calendar

Last Earnings
11/08/2022
Today
1/27/2023
Next Earnings (Estimated)
2/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SAGE
Employees
471
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$48.29
High Stock Price Forecast
$73.00
Low Stock Price Forecast
$37.00
Forecasted Upside/Downside
+7.4%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
12 Analysts

Profitability

Net Income
$-457,890,000.00
Net Margins
-7,895.27%
Pretax Margin
-7,895.27%

Debt

Sales & Book Value

Annual Sales
$6.31 million
Book Value
$29.35 per share

Miscellaneous

Free Float
56,638,000
Market Cap
$2.68 billion
Optionable
Optionable
Beta
1.17

Key Executives

  • Barry E. GreeneBarry E. Greene
    President, Chief Executive Officer & Director
  • Kimi E. Iguchi
    Chief Financial Officer
  • Al Robichaud
    Chief Scientific Officer
  • Amy Schacterle
    Senior VP-Research & Development Strategy
  • Matt Lasmanis
    Chief Technology & Innovation Officer













SAGE Stock - Frequently Asked Questions

Should I buy or sell Sage Therapeutics stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sage Therapeutics in the last twelve months. There are currently 9 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SAGE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAGE, but not buy additional shares or sell existing shares.
View SAGE analyst ratings
or view top-rated stocks.

What is Sage Therapeutics' stock price forecast for 2023?

12 brokers have issued 1 year price targets for Sage Therapeutics' shares. Their SAGE share price forecasts range from $37.00 to $73.00. On average, they anticipate the company's share price to reach $48.29 in the next twelve months. This suggests a possible upside of 7.4% from the stock's current price.
View analysts price targets for SAGE
or view top-rated stocks among Wall Street analysts.

How have SAGE shares performed in 2023?

Sage Therapeutics' stock was trading at $38.14 at the beginning of 2023. Since then, SAGE stock has increased by 17.9% and is now trading at $44.97.
View the best growth stocks for 2023 here
.

When is Sage Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our SAGE earnings forecast
.

How were Sage Therapeutics' earnings last quarter?

Sage Therapeutics, Inc. (NASDAQ:SAGE) posted its quarterly earnings data on Tuesday, November, 8th. The biopharmaceutical company reported ($2.31) EPS for the quarter, missing the consensus estimate of ($2.16) by $0.15. The biopharmaceutical company had revenue of $1.74 million for the quarter, compared to analyst estimates of $1.68 million. Sage Therapeutics had a negative net margin of 7,895.27% and a negative trailing twelve-month return on equity of 32.76%.

What other stocks do shareholders of Sage Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sage Therapeutics investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Netflix (NFLX), Roku (ROKU), QUALCOMM (QCOM) and Bristol-Myers Squibb (BMY).

What is Sage Therapeutics' stock symbol?

Sage Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."

Who are Sage Therapeutics' major shareholders?

Sage Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Pinnacle Associates Ltd. (0.30%), Baillie Gifford & Co. (0.16%), Allspring Global Investments Holdings LLC (0.15%), Hennion & Walsh Asset Management Inc. (0.12%), Pendal Group Ltd (0.01%) and Inspire Investing LLC (0.01%). Insiders that own company stock include Barry E Greene, Barry E Greene, George Golumbeski and James M Frates.
View institutional ownership trends
.

How do I buy shares of Sage Therapeutics?

Shares of SAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sage Therapeutics' stock price today?

One share of SAGE stock can currently be purchased for approximately $44.97.

How much money does Sage Therapeutics make?

Sage Therapeutics (NASDAQ:SAGE) has a market capitalization of $2.68 billion and generates $6.31 million in revenue each year. The biopharmaceutical company earns $-457,890,000.00 in net income (profit) each year or ($8.63) on an earnings per share basis.

How many employees does Sage Therapeutics have?

The company employs 471 workers across the globe.

How can I contact Sage Therapeutics?

Sage Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The official website for the company is www.sagerx.com. The biopharmaceutical company can be reached via phone at (617) 299-8380, via email at ir@sagerx.com, or via fax at 617-299-8379.

This page (NASDAQ:SAGE) was last updated on 1/27/2023 by MarketBeat.com Staff